Supernus Pharmaceuticals Downgraded to “Neutral” at Zacks (SUPN)
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Friday, American Banking & Market News reports. They currently have a $7.90 price objective on the stock. Zacks‘ price target would suggest a potential upside of 20.61% from the stock’s previous close.
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 0.61% on Friday, hitting $6.59. The stock had a trading volume of 192,910 shares. Supernus Pharmaceuticals has a one year low of $4.45 and a one year high of $14.98. The stock has a 50-day moving average of $6.89 and a 200-day moving average of $6.36. The company’s market cap is $203.9 million.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings data on Tuesday, August 13th. The company reported ($0.89) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.65) by $0.24. The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.91 million. During the same quarter last year, the company posted ($0.61) earnings per share. Supernus Pharmaceuticals’s revenue was up 207.7% compared to the same quarter last year. Analysts expect that Supernus Pharmaceuticals will post $-2.50 EPS for the current fiscal year.
Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.